Currently, out of the existing stock ratings of David Amsellem - 248 which are a Buy (75.84%), 69 which are a Hold (21.1%), 10 which are a Sell (3.06%)

David Amsellem

Work Performance Price Targets & Ratings Chart

Analyst David Amsellem works at PIPER SANDLER and is covering the Healthcare sector with 641 price targets and ratings displayed on 33 stocks.

David Amsellem's average stock forecast success ratio is 51.08% with an average time for price targets to be met of 239.21 days.

Most recent stock forecast was given on RVNC, Revance Therapeutics at 20-Sep-2023.

Wall Street Analyst David Amsellem

Analyst best performing recommendations are on REPH (RECRO PHARMA).
The best stock recommendation documented was for NBIX (NEUROCRINE BIOSCIENCES) at 12/19/2013. The price target of $17 was fulfilled within 19 days with a profit of $7.88 (86.4%) receiving and performance score of 45.48.

Average potential price target upside

of $27.52 (20.47%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $40.31 (18.05%) on AGN.
of $12.72 (32.39%) on PCRX (PACIRA BIOSCIENCES).

ADMS Adamas Pharmaceuticals AGN AKRX AMPH Amphastar Pharmaceuticals AMRX Amneal Pharmaceuticals ATRS Antares Pharma BDSI BioDelivery Sciences International BHC Bausch Health Companies COLL Collegium Pharmaceutical EGRX Eagle Pharmaceuticals ENDP Endo International plc HZNP Horizon Therapeutics PublicCompany INSY JAZZ Jazz Pharmaceuticals plc MNK NBIX Neurocrine Biosciences PCRX Pacira BioSciences RVNC Revance Therapeutics SUPN Supernus Pharmaceuticals TEVA Teva Pharmaceutical Industries CARA Cara Therapeutics EVFM Evofem Biosciences OGN OPTN OptiNose REPH Recro Pharma ASRT VTRS ALKS Alkermes plc AVDL Avadel Pharmaceuticals plc BXRX Baudax Bio HRMY Harmony Biosciences Holdings NOVN XERS Xeris Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Carl Byrnes (NORTHLAND CAPITAL MARKET)